{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Precision+Treatment&page=12",
    "query": {
      "intervention": "Precision Treatment",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 335,
    "total_pages": 34,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Precision+Treatment&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Precision+Treatment&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T17:33:59.806Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06357975",
      "title": "Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Radiologic Examination",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2016-07-29",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-31T17:33:59.806Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06357975"
    },
    {
      "nct_id": "NCT06090513",
      "title": "Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Advanced Cancer",
        "Solid Tumor, Adult",
        "Myeloid Malignancy"
      ],
      "interventions": [
        {
          "name": "Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "limited genetic testing or no testing",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Bien-Willner Physicians Group PA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2024-10-18",
      "completion_date": "2026-10-18",
      "has_results": false,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-10-31T17:33:59.806Z",
      "location_count": 1,
      "location_summary": "Rock Hill, South Carolina",
      "locations": [
        {
          "city": "Rock Hill",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06090513"
    },
    {
      "nct_id": "NCT06896162",
      "title": "PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Solid Tumor Malignancies",
        "Metastatic Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Lung Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Expert Review",
          "type": "OTHER"
        },
        {
          "name": "Blood or tissue samples collection.",
          "type": "OTHER"
        },
        {
          "name": "The Precision Oncology Navigation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2025-06-27",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-10-31T17:33:59.806Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06896162"
    },
    {
      "nct_id": "NCT03223662",
      "title": "Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Esophageal Adenocarcinoma",
        "Esophageal Squamous Cell Cancer",
        "Esophageal Neoplasms",
        "Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Chemoradiotherapy",
          "type": "OTHER"
        },
        {
          "name": "Esophagectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 2,
      "start_date": "2017-10-31",
      "completion_date": "2018-07-27",
      "has_results": true,
      "last_update_posted_date": "2018-10-30",
      "last_synced_at": "2026-10-31T17:33:59.806Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03223662"
    },
    {
      "nct_id": "NCT03370510",
      "title": "Translating Neuroprediction Into Precision Medicine Via Brain Priming",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        },
        {
          "name": "Pivotal Response Treatment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "9 Years",
        "sex": "ALL",
        "summary": "5 Years to 9 Years"
      },
      "enrollment_count": 5,
      "start_date": "2018-12-07",
      "completion_date": "2021-07-28",
      "has_results": true,
      "last_update_posted_date": "2022-08-09",
      "last_synced_at": "2026-10-31T17:33:59.806Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03370510"
    },
    {
      "nct_id": "NCT02191358",
      "title": "YouScript IMPACT Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adverse Drug Events",
        "Adverse Drug Reactions",
        "Drug Interaction Potentiation",
        "Drug Metabolism, Poor, CYP2D6-RELATED",
        "Drug Metabolism, Poor, CYP2C19-RELATED",
        "Cytochrome P450 Enzyme Deficiency",
        "Cytochrome P450 CYP2D6 Enzyme Deficiency",
        "Cytochrome P450 CYP2C9 Enzyme Deficiency",
        "Cytochrome P450 CYP2C19 Enzyme Deficiency",
        "Cytochrome P450 CYP3A Enzyme Deficiency",
        "Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant",
        "Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant",
        "Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Genelex Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2014-10",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2017-03-01",
      "last_synced_at": "2026-10-31T17:33:59.806Z",
      "location_count": 7,
      "location_summary": "Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Fall River",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02191358"
    },
    {
      "nct_id": "NCT07293585",
      "title": "Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Neurovascular sparing stereotactic body radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 200,
      "start_date": "2025-12-16",
      "completion_date": "2036-12-16",
      "has_results": false,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-10-31T17:33:59.806Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07293585"
    },
    {
      "nct_id": "NCT05509049",
      "title": "Precision Nudging Drives Wellness Visit Attendance at Scale",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Women's Health",
        "Annual Visit",
        "Well Visit",
        "Health Behavior",
        "Prevention"
      ],
      "interventions": [
        {
          "name": "Precision nudging",
          "type": "OTHER"
        },
        {
          "name": "Standard of care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Lirio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 65 Years · Female only"
      },
      "enrollment_count": 30068,
      "start_date": "2022-09-07",
      "completion_date": "2024-01-09",
      "has_results": false,
      "last_update_posted_date": "2024-01-17",
      "last_synced_at": "2026-10-31T17:33:59.806Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05509049"
    },
    {
      "nct_id": "NCT07859709",
      "title": "The CLASP III TR CED Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tricuspid Regurgitation",
        "Heart Valve Diseases",
        "Heart Diseases",
        "Cardiovascular Diseases",
        "Tricuspid Valve Insufficiency"
      ],
      "interventions": [
        {
          "name": "PASCAL Precision system Treated",
          "type": "DEVICE"
        },
        {
          "name": "Medicare Eligible Untreated Patients",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Edwards Lifesciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 2350,
      "start_date": "2026-10-15",
      "completion_date": "2033-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-31T17:33:59.806Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07859709"
    },
    {
      "nct_id": "NCT04541108",
      "title": "Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Rilvegostomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Volrustomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sabestomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD9592",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD9592 + Rilvegostomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Volrustomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Sabestomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Presage Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-07-26",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-31T17:33:59.806Z",
      "location_count": 9,
      "location_summary": "Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541108"
    }
  ]
}